Dactylitis in psoriatic arthritis: Prevalence and response to therapy in the biologic ERA

Journal of Rheumatology

Volumn 40, Issue 8, 2013, Pages 1357-1359

  Gladman, Dafna D ^a,c   Ziouzina, Olga ^b   Thavaneswaran, Arane ^c   Chandran, Vinod ^c  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

^c TORONTO WESTERN HOSPITAL   (Canada)

Author keywords

Biologics; Dactylitis; Disease modifying antirheumatic drug; Inflammation; Spondyloarthritis

Indexed keywords

DISEASE MODIFYING ANTIRHEUMATIC DRUG; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ADULT; AGE DISTRIBUTION; ARTICLE; BIOLOGICAL THERAPY; COHORT ANALYSIS; CONTROLLED STUDY; DACTYLITIS; DISEASE ASSOCIATION; DISEASE DURATION; DRUG EFFICACY; FEMALE; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIORITY JOURNAL; PSORIASIS AREA AND SEVERITY INDEX; PSORIATIC ARTHRITIS; SEX DIFFERENCE; TREATMENT RESPONSE;

BIOLOGICS; DACTYLITIS; DISEASE-MODIFYING ANTIRHEUMATIC DRUG; INFLAMMATION; SPONDYLOARTHRITIS;

ADULT; ANTIRHEUMATIC AGENTS; ARTHRITIS, PSORIATIC; BIOLOGICAL PRODUCTS; COHORT STUDIES; COMORBIDITY; FEMALE; FINGER JOINT; HUMANS; INFLAMMATION; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PREVALENCE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84881464846     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.130163     Document Type: Article

References (14)

1. Coates LC, Helliwell PS. Disease measurement-enthesitis, skin, nails, spine and dactylitis. Best Pract Res Clin Rheumatol 2010;24:659-70.
2. Brockbank J, Stein M, Schentag CT, Gladman DD. Dactylitis in psoriatic arthritis (PsA): A marker for disease severity? Ann Rheum Dis 2005;62:188-90.
3. Taylor WJ, Gladman DD, Helliwell PS, Marchesoni A, Mease P, Mielants H. Classification criteria for psoriatic arthritis: Development of new criteria from a large international study. Arthritis Rheum 2006;54:2665-73.
4. Healy PJ, Helliwell PS. Dactylitis: pathogenesis and clinical considerations. Curr Rheumatol Rep 2006;8:338-41.
5. Saad AA, Symmons DP, Noyce PR, Ashcroft DM. Risks and benefits of tumor necrosis factor-alpha inhibitors in the management of psoriatic arthritis: Systematic review and metaanalysis of randomized controlled trials. J Rheumatol 2008;35:883-90.
6. Helliwell PS. Therapies for dactylitis in psoriatic arthritis. A systematic review. J Rheumatol 2006;33:1439-41.
7. Antoni CE, Kavanaugh A, Kirkham B, Tutuncu Z, Burmester GR, Schneider U, et al. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: Results from the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT). Arthritis Rheum 2005;52:1227-36.
8. Kavanaugh A, Mease P. Treatment of psoriatic arthritis with tumor necrosis factor inhibitors: Longer-term outcomes including enthesitis and dactylitis with golimumab treatment in the Longterm Extension of a Randomized, Placebo-controlled Study (GO-REVEAL). J Rheumatol Suppl. 2012 Jul;89:90-3.
9. Gladman DD, Sampalis JS, Illouz O, Guerette B. Responses to adalimumab in patients with active psoriatic arthritis who have not adequately responded to prior therapy: Effectiveness and safety results from an open-label study. J Rheumatol 2010;37:1898-906.
10. Salvarani C, Pipitone N, Catanoso M, Chiarolanza I, Boiardi L, Caruso A, et al. Adalimumab in psoriatic arthritis. J Rheumatol Suppl. 2012 Jul;89:77-81.
11. Gladman DD, Bombardier C, Thorne C, Haraoui B, Khraishi M, Rahman P, et al. Effectiveness and safety of etanercept in patients with psoriatic arthritis in a Canadian clinical practice setting: The REPArE (Rating Evaluations in Psoriatic Arthritis with Enbrel) trial. J Rheumatol 2011;38:1355-62.
12. Gladman DD, Chandran V. Observational cohort studies: Lessons learnt from the University of Toronto Psoriatic Arthritis Program. Rheumatology 2011;50:25-31.
13. Carneiro JN, Paula AP, Martins GA. Psoriatic arthritis in patients with psoriasis: Evaluation of clinical and epidemiological features in 133 patients followed at the University Hospital of Brasilia. An Bras Dermatol 2012;87:539-44.
14. Ritchlin CT, Kavanaugh A, Gladman DD, Mease PJ, Boehncke WH, de Vlam K, et al. Treatment recommendations for psoriatic arthritis. Ann Rheum Dis 2009;68:1387-94.